Literature DB >> 29808718

Targeting of PP2Cδ By a Small Molecule C23 Inhibits High Glucose-Induced Breast Cancer Progression In Vivo.

Ke Wu1,2, Xiaoting Yu3, Zhimin Huang4, Donghui Zhu5, Xianghua Yi3, Ying-Li Wu4, Qiongyu Hao1, Kevin T Kemp1, Yahya Elshimali1, Roshni Iyer6, Kytai Truong Nguyen6, Shilong Zheng7,8, Guanglin Chen9, Qiao-Hong Chen9, Guangdi Wang7,8, Jaydutt V Vadgama1,10, Yong Wu1,10.   

Abstract

Aims: Epidemiologic evidence indicates that diabetes may increase risk of breast cancer (BC) and mortality in patients with cancer. The pathophysiological relationships between diabetes and cancer are not fully understood, and personalized treatments for diabetes-associated BC are urgently needed.
Results: We observed that high glucose (HG), via activation of nuclear phosphatase PP2Cδ, suppresses p53 function, and consequently promotes BC cell proliferation, migration, and invasion. PP2Cδ expression is higher in tumor tissues from BC patients with hyperglycemia than those with normoglycemia. The mechanisms underlying HG stimulation of PP2Cδ involve classical/novel protein kinase-C (PKC) activation and GSK3β phosphorylation. Reactive oxygen species (ROS)/NF-κB pathway also mediates HG induction of PP2Cδ. Furthermore, we identified a 1,5-diheteroarylpenta-1,4-dien-3-one (Compound 23, or C23) as a novel potent PP2Cδ inhibitor with a striking cytotoxicity on MCF-7 cells through cell-based screening assay for growth inhibition and activity of a group of curcumin mimics. Beside directly inhibiting PP2Cδ activity, C23 blocks HG induction of PP2Cδ expression via heat shock protein 27 (HSP27) induction and subsequent ablation of ROS/NF-κB activation. C23 can thus significantly block HG-triggered inhibition of p53 activity, leading to the inhibition of cancer cell proliferation, migration, and invasion. In addition, hyperglycemia promotes BC development in diabetic nude mice, and C23 inhibits the xenografted BC tumor growth. Conclusions and Innovation: Our findings elucidate mechanisms that may have contributed to diabetes-associated BC progression, and provide the first evidence to support the possible alternative therapeutic approach to BC patients with diabetes. Antioxid. Redox Signal. 30, 1983-1998.

Entities:  

Keywords:  GSK3β; NF-κB; PP2Cδ; breast cancer; diabetes; high glucose; p53

Mesh:

Substances:

Year:  2018        PMID: 29808718      PMCID: PMC6486665          DOI: 10.1089/ars.2017.7486

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   7.468


  57 in total

Review 1.  Comparative protein structure modeling of genes and genomes.

Authors:  M A Martí-Renom; A C Stuart; A Fiser; R Sánchez; F Melo; A Sali
Journal:  Annu Rev Biophys Biomol Struct       Date:  2000

2.  Two cases of malignant tumors with metastases apparently treated successfully with hypoglycemic coma.

Authors:  S KOROLJOW
Journal:  Psychiatr Q       Date:  1962-04

3.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

4.  p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation.

Authors:  M Takekawa; M Adachi; A Nakahata; I Nakayama; F Itoh; H Tsukuda; Y Taya; K Imai
Journal:  EMBO J       Date:  2000-12-01       Impact factor: 11.598

Review 5.  Oncogenic alterations of metabolism.

Authors:  C V Dang; G L Semenza
Journal:  Trends Biochem Sci       Date:  1999-02       Impact factor: 13.807

6.  Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation.

Authors:  T Rogalla; M Ehrnsperger; X Preville; A Kotlyarov; G Lutsch; C Ducasse; C Paul; M Wieske; A P Arrigo; J Buchner; M Gaestel
Journal:  J Biol Chem       Date:  1999-07-02       Impact factor: 5.157

7.  Fasting glucose is a risk factor for breast cancer: a prospective study.

Authors:  Paola Muti; Teresa Quattrin; Brydon J B Grant; Vittorio Krogh; Andrea Micheli; Holger J Schünemann; Malathi Ram; Jo L Freudenheim; Sabina Sieri; Maurizio Trevisan; Franco Berrino
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-11       Impact factor: 4.254

8.  Risk of breast cancer in relation to anthropometry, blood pressure, blood lipids and glucose metabolism: a prospective study within the Malmö Preventive Project.

Authors:  J Manjer; R Kaaks; E Riboli; G Berglund
Journal:  Eur J Cancer Prev       Date:  2001-02       Impact factor: 2.497

9.  Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.

Authors:  Dmitry V Bulavin; Oleg N Demidov; Shin'ichi Saito; Paivikki Kauraniemi; Crissy Phillips; Sally A Amundson; Concetta Ambrosino; Guido Sauter; Angel R Nebreda; Carl W Anderson; Anne Kallioniemi; Albert J Fornace; Ettore Appella
Journal:  Nat Genet       Date:  2002-05-20       Impact factor: 38.330

10.  Role of glucose and ketone bodies in the metabolic control of experimental brain cancer.

Authors:  T N Seyfried; T M Sanderson; M M El-Abbadi; R McGowan; P Mukherjee
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

View more
  6 in total

1.  The role of PPM1D in cancer and advances in studies of its inhibitors.

Authors:  Wenhong Deng; Jieqing Li; Kimberly Dorrah; Denise Jimenez-Tapia; Brando Arriaga; Qiongyu Hao; Wei Cao; Zhaoxia Gao; Jay Vadgama; Yong Wu
Journal:  Biomed Pharmacother       Date:  2020-01-29       Impact factor: 7.419

2.  A Novel Metabolic Reprogramming Strategy for the Treatment of Diabetes-Associated Breast Cancer.

Authors:  Qiongyu Hao; Zhimin Huang; Qun Li; Dingxie Liu; Piwen Wang; Kun Wang; Jieqing Li; Wei Cao; Wenhong Deng; Ke Wu; Rui Su; Zhongmin Liu; Jay Vadgama; Yong Wu
Journal:  Adv Sci (Weinh)       Date:  2022-01-12       Impact factor: 16.806

3.  Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state.

Authors:  Peter G Miller; Murugappan Sathappa; Jamie A Moroco; Wei Jiang; Yue Qian; Sumaiya Iqbal; Qi Guo; Andrew O Giacomelli; Subrata Shaw; Camille Vernier; Besnik Bajrami; Xiaoping Yang; Cerise Raffier; Adam S Sperling; Christopher J Gibson; Josephine Kahn; Cyrus Jin; Matthew Ranaghan; Alisha Caliman; Merissa Brousseau; Eric S Fischer; Robert Lintner; Federica Piccioni; Arthur J Campbell; David E Root; Colin W Garvie; Benjamin L Ebert
Journal:  Nat Commun       Date:  2022-06-30       Impact factor: 17.694

Review 4.  High glucose: an emerging association between diabetes mellitus and cancer progression.

Authors:  Suangson Supabphol; Wunchana Seubwai; Sopit Wongkham; Charupong Saengboonmee
Journal:  J Mol Med (Berl)       Date:  2021-05-26       Impact factor: 4.599

5.  PP2Cδ inhibits p300-mediated p53 acetylation via ATM/BRCA1 pathway to impede DNA damage response in breast cancer.

Authors:  Qun Li; Qiongyu Hao; Wei Cao; Jieqing Li; Ke Wu; Yahya Elshimali; Donghui Zhu; Qiao-Hong Chen; Guanglin Chen; Jonathan R Pollack; Jay Vadgama; Yong Wu
Journal:  Sci Adv       Date:  2019-10-16       Impact factor: 14.957

6.  Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4, a novel oncogenic long noncoding RNA.

Authors:  Qiongyu Hao; Piwen Wang; Pranabananda Dutta; Seyung Chung; Qun Li; Kun Wang; Jieqing Li; Wei Cao; Wenhong Deng; Qing Geng; Katrina Schrode; Magda Shaheen; Ke Wu; Donghui Zhu; Qiao-Hong Chen; Guanglin Chen; Yahya Elshimali; Jay Vadgama; Yong Wu
Journal:  Cell Death Dis       Date:  2020-12-11       Impact factor: 9.685

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.